Abstract: cDNAs encoding a class of receptors, including the IL-8 receptors, have been identified in human tissue. Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.
Abstract: Proteins produced by human lymphocytes are described, particularly a protein which is expressed on their surface. DNA sequences coding these proteins and their pharmaceutical and biological uses are also described.
Type:
Grant
Filed:
April 4, 1995
Date of Patent:
June 30, 1998
Assignees:
Institut National de la Sante Et de la Recherche Medicale, Institut Gustave Roussy
Abstract: The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibody 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626. In a specific embodiment, the 4G9 antibody is used in a sandwich ELISA to detect ApoB-AGE, IgG-AGE, collagen-AGE, serum-AGE peptides and proteins and urinary-AGE peptides and proteins.
Abstract: Compositions of, genetic constructions coding for, and methods for producing single-chain and multivalent immunoeffector antigen-binding fusion proteins are provided by the invention. Antigen-binding fusion proteins having phospholipase A activating protein and/or tumor necrosis factor fragments are also provided by the invention. Genetic sequences coding for single-chain and multivalent immunoeffector antigen-binding fusion proteins are disclosed.
Type:
Grant
Filed:
August 16, 1995
Date of Patent:
June 16, 1998
Assignee:
Enzon Inc.
Inventors:
Marc Whitlow, David Filpula, Robert Shorr
Abstract: Disclosed is a process of activating patient-derived mononuclear cells by exposing the cells in vitro to substances wo generate immunoreactive cells. The ex vivo activated cells are then reinfused into the patient to enhance the immune system to treat various forms of cancer, infectious diseases, autoimmune diseases or immune deficiency diseases.
Abstract: Human monoclonal antibodies and fragments thereof which bind and neutralize respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell lines producing the monoclonal antibodies.
Type:
Grant
Filed:
December 10, 1993
Date of Patent:
June 9, 1998
Assignee:
The Scripps Research Institute
Inventors:
Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
Abstract: The present invention includes methods and compositions for treating humans and other animals intoxicated with at least one clostridial toxin by administration of antitoxin. In particular, the antitoxin directed against these toxins is produced in avian species. This avian antitoxin is designed so as to be orally administerable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution).
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
June 9, 1998
Assignee:
Ophidian Pharmaceuticals, Inc.
Inventors:
James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
Abstract: Disclosed is a method of inhibiting a rejection response by a primate to a transplanted organ. One exposes the primate to a mutant diphtheria toxin linked to anti-CD3 antibody so as to largely eliminate the host's peripheral blood T cell lymphocyte population. At the same time as, or after, the exposure step one administers to the primate's thymus gland donor lymphocytes. Transplantation of the organ follows. The primate is tolerized to the transplanted organ.
Type:
Grant
Filed:
April 11, 1997
Date of Patent:
June 9, 1998
Assignees:
Wisconsin Alumni Research Foundation, David M. Neville, Jr.
Inventors:
Stuart J. Knechtle, Jue Wang, Jon A. Wolff, David M. Neville, Jr.
Abstract: Compositions of, genetic constructions coding for, and methods for producing single-chain and multivalent immunoeffector antigen-binding fusion proteins are provided by the invention. Antigen-binding fusion proteins having phospholipase A activating protein and/or tumor necrosis factor fragments are also provided by the invention. Genetic sequences coding for single-chain and multivalent immunoeffector antigen-binding fusion proteins are disclosed.
Type:
Grant
Filed:
October 13, 1994
Date of Patent:
June 9, 1998
Assignee:
Enzon, Inc.
Inventors:
Marc Whitlow, David Filpula, Robert Shorr
Abstract: A method for the selective depletion of activated CD4.sup.+ T-cells in vivo by using immunotoxins comprising the OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4.sup.+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis. This type of therapy is also beneficial for eradicating CD4.sup.+ T-cell lymphomas and alloreactive CD4.sup.+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.
Type:
Grant
Filed:
February 4, 1994
Date of Patent:
June 2, 1998
Inventors:
Andrew D. Weinberg, Arthur A. Vandenbark
Abstract: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.
Abstract: The present invention relates to monoclonal antibodies that are distinguished by a high degree of selectivity and affinity towards herbicides from the group of the sulfonylureas, especially towards sulfonylurea herbicides of formula (A) ##STR1## wherein X is a mono- or di-substituted 6-membered heterocycle having from one to three nitrogen atoms and bonded via carbon, but is preferably mono- or di-substituted s-triazine or pyrimidine; andn is an integer from 0 to 4, preferably the number 1, and that are therefore outstandingly suitable for use in an immunoassay for the rapid and effective detection of the said sulfonylurea herbicides in soil, water or air samples or in plant extracts, and to methods for the production of said monoclonal antibodies. The present invention relates also to hybridoma cell lines that produce said monoclonal antibodies and to immunological detection methods using said monoclonal antibodies, and to test kits that may be used in those detection methods.
Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
May 26, 1998
Assignee:
Xoma Corporation
Inventors:
Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
Abstract: Egg yolks and egg yolk fractions containing effective therapeutic concentrations of avian antibodies against parasitic antigen, and a method of providing passive immunization for the prevention or treatment of intestinal parasitosis by enteral administration of egg yolk antibodies harvested from hyperimmunized avian hens. Also provided are pharmaceutical formulations comprising the egg yolk antibodies.
Type:
Grant
Filed:
December 5, 1994
Date of Patent:
May 19, 1998
Assignee:
Arizona Board of Regents on behalf of The University of Arizona
Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a preselected antigen by the binding site of each polypeptide chain when administered to a mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
May 19, 1998
Assignees:
Chiron Corporation, Creative BioMolecules, Inc.
Inventors:
James S. Huston, L. L. Houston, David B. Ring, Hermann Oppermann
Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.
Abstract: The present invention relates to disulfide-stabilized recombinant polypeptide molecules which have the binding ability and specificity for another peptide, such as the variable region of an antibody molecule. Methods of producing these molecules and nucleic acid sequences encoding these molecules are also described. In particular, the invention discloses Fv antibody fragments stabilized by a disulfide bond connecting the V.sub.H and V.sub.L regions of the Fv fragment. The .alpha. and .beta. chains of T cell receptors may be similarly stabilized by means described in the invention.
Type:
Grant
Filed:
June 14, 1993
Date of Patent:
May 5, 1998
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Ira H. Pastan, Byungkook Lee, Sun-Hee Jung, Ulrich Brinkmann
Abstract: Polypeptides have been discovered which exhibit high specific VIII:C coagulant activity. Monoclonal antibodies to the polypeptides are also disclosed.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
May 5, 1998
Assignee:
The Scripps Research Institute
Inventors:
Theodore S. Zimmerman, Carol A. Fulcher
Abstract: The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibody 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626. In a specific embodiment, the 4G9 antibody is used in a sandwich ELISA to detect ApoB-AGE, IgG-AGE, collagen-AGE, serum-AGE peptides and proteins and urinary-AGE peptides and proteins.
Abstract: A method for increasing feed conversion efficiency in mammals, such as swine, wherein the mammal is fed a diet containing an antibody produced using the enzyme urease as the antigen.